目的:对恶性滋养细胞肿瘤按2000年国际妇产科联盟(FIGO)预后评分标准评分并选择治疗方案的疗效进行评价.方法:恶性滋养细胞肿瘤患者169例,治疗前按2000年FIGO预后评分标准进行分期及评分,以此选择治疗方案.结果:169例患者中,绒毛膜癌49例,30例为高危,19例为低危；侵蚀性葡萄胎120例,8例为高危,112例为低危.治疗原则:低危患者以单药化疗为主,高危患者采用多药联合化疗.本组患者的1年、3年、5年生存率分别为98.8％、97.6％及96.9％.无一例因毒副反应或并发症而死亡.结论:治疗前应用2000年FIGO顸后评分系统选择恶性滋养细胞肿瘤治疗方案取得较好的临床效果,新分期系统对指导临床治疗有重大意义.%Objective:To evaluate the prognostic score at the 2000 International Federation of Gynecology and Obstetrics (FIGO)standard rated the efficacy of the treatment for malignant trophoblastic neoplasia.Methods:169 cases of malignant trophoblastic tumor,before treatment,according to the 2000 FIGO prognostic score were determined risk factors,in order to select treatment options.Results:Obstetrics(FIGO) scoring system published in 2000,appropriate treatments were selected for the different patients.Among the 169 cases there were 49 cases of choriocarcinomas and 30 of which were with high-risk factors,the other 19 cases were with low-risk factors； 8 of 120 cases of invasive moles which were with high-risk factors and the others were with low-risk factors； The chemotherapy principle was that one agent was used for those patients with low-risk factors and two or multiple-agents were used for those patients with high-risk factors.Among all patients,the one-year,three-year and five-year survival rates were 98.8％,97.6％ and 96.9％ respectively.No patient died of drug toxicity or complication.Conclusion:Selection of treatment approaches according to the prognostic assessment of malignant trophoblastic neoplasia before treatment could lead to promising survival rate with no uncurable complication and toxic effects.
展开▼
